Deals

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035
ADC / XDCAdlai Nortye

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035

Adlai Nortye (NASDAQ: ANL) announced that it has separately entered into clinical trial collaboration and drug supply agreements with Eli Lilly and Company (NYSE: LLY) and Merck KGaA, Darmstadt, Germany…

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Cloudbreak Pharma's IPO Raises HKD 522M for Ophthalmic Drug Development
Cloudbreak PharmaIPO

Cloudbreak Pharma’s IPO Raises HKD 522M for Ophthalmic Drug Development

Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study
Auto-immuneFormation Bio

Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study

Illumina to Acquire SomaLogic for $350M to Expand Proteomics Tech Integration
FinanceIllumina

Illumina to Acquire SomaLogic for $350M to Expand Proteomics Tech Integration

Denovo Biopharma Inks Licensing Deal With Chuang Yi for DB104 in Taiwan
Denovo Biopharma

Denovo Biopharma Inks Licensing Deal With Chuang Yi for DB104 in Taiwan

Show More